Lower toxicity with targeted anticancer agents in phase I trials

被引：0
|
作者：
机构：
来源：
Reactions Weekly | 2012年 / 1416卷 / 1期
关键词：
Independent Predictor; Component Variable; National Cancer Institute; Anticancer Agent; Advanced Cancer;
D O I：
10.2165/00128415-201214160-00005
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：3 / 3
相关论文
共 50 条
  • [41] Immunomodulation by targeted anticancer agents
    Petroni, Giulia
    Buque, Aitziber
    Zitvogel, Laurence
    Kroemer, Guido
    Galluzzi, Lorenzo
    CANCER CELL, 2021, 39 (03) : 310 - 345
  • [42] NEW ANTICANCER AGENTS IN PHASE-I/II
    QUEISSER, W
    ONKOLOGIE, 1992, 15 (06): : 454 - 462
  • [43] Publication biases and phase II trials investigating anticancer targeted therapies
    Penel, Nicolas
    Adenis, Antoine
    INVESTIGATIONAL NEW DRUGS, 2009, 27 (03) : 287 - 288
  • [44] Publication biases and phase II trials investigating anticancer targeted therapies
    Nicolas Penel
    Antoine Adenis
    Investigational New Drugs, 2009, 27 : 287 - 288
  • [45] Systematic review of pediatric oncology phase I trials: Toxicity and outcomes in the era of targeted therapies.
    Cohen, Julia Wanda
    Akshintala, Srivandana
    Kane, Eli
    Steinberg, Seth M.
    Widemann, Brigitte C.
    Shah, Nirali N.
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
  • [46] Cardiac Toxicity of Anticancer Agents
    Alessandro Colombo
    Carlo Cipolla
    Marta Beggiato
    Daniela Cardinale
    Current Cardiology Reports, 2013, 15
  • [47] Cardiac Toxicity of Anticancer Agents
    Colombo, Alessandro
    Cipolla, Carlo
    Beggiato, Marta
    Cardinale, Daniela
    CURRENT CARDIOLOGY REPORTS, 2013, 15 (05)
  • [48] Clinical benefit in Phase-I trials of novel molecularly targeted agents: does dose matter?
    S Postel-Vinay
    H-T Arkenau
    D Olmos
    J Ang
    J Barriuso
    S Ashley
    U Banerji
    J De-Bono
    I Judson
    S Kaye
    British Journal of Cancer, 2009, 100 : 1373 - 1378
  • [49] Clinical benefit in Phase-I trials of novel molecularly targeted agents: does dose matter?
    Postel-Vinay, S.
    Arkenau, H-T
    Olmos, D.
    Ang, J.
    Barriuso, J.
    Ashley, S.
    Banerji, U.
    De-Bono, J.
    Judson, I.
    Kaye, S.
    BRITISH JOURNAL OF CANCER, 2009, 100 (09) : 1373 - 1378
  • [50] Phase I Trials of Molecularly Targeted Agents: Should We Pay More Attention to Late Toxicities?
    Postel-Vinay, Sophie
    Gomez-Roca, Carlos
    Molife, L. Rhoda
    Anghan, Bhavesh
    Levy, Antonin
    Judson, Ian
    De Bono, Johann
    Soria, Jean-Charles
    Kaye, Stan
    Paoletti, Xavier
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (13) : 1728 - 1735
12345